About 20 years ago, the industry-wide cost of a new drug was around $100 million (USD). Toward the end of the 1980s, that cost had risen to $250 million. Biological testing had entered the high-throughput screening era, creating the ability to test more compounds than previously achievable. This added to the demand for more compounds with new properties. In the early days of modern drug discovery, 5000 to 10 000 compounds would be evaluated for each drug development lead found. A decade after the introduction of highthroughput screening technologies, this efficiency in generating drug development leads had declined to 120 000 compounds tested per lead. 1 In the last few years, this efficiency generally has declined further still. Among the reasons for the declining performance are the molecular targets being pursued (eg, more protein-protein interactions) and the high attrition rates when testing for efficacy and safety needed in drug leads. Into this climate of demand for large numbers of novel compounds, combinatorial chemistry was born. Combinatorial chemistry was a technological revolution because it provided a means to generate new compoundsranging from a few to many thousands of different molecules-in a short period of time. It is also a method generally accessible to laboratories big and small, thus making the discovery of small molecule drugs no longer the exclusive province of major drug companies.
In some ways, however, combinatorial chemistry has been disappointing for pharmaceutical scientists. A decade after its introduction, the industry-wide cost of developing a new drug has ballooned to the $500-600 million range, and we still see only a few exciting drug development leads entering our pipelines. Indeed, generic combinatorial chemistry collections have performed worse than traditional drug company compound collections in generating leads. In this Perspective, I will briefly introduce the basic concepts of combinatorial chemistry, describe its strengths and weaknesses with an eye to efficiencies, and highlight some ongoing changes to enhance performance. The scope will be restricted to small compounds made by synthetic chemistry, and not biologically generated libraries such as phage display.
Combinatorial chemistry applies permutational design to synthetic strategies. Figure 1 illustrates prototypical combinatorial compounds made and the common methods to make them. The first generation of combinatorial chemistry was based on polymer chemistry. These comprised peptide and oligonucleotide libraries. [2] [3] [4] [5] In the case of peptide libraries, each position of a peptide chain was a point of randomization for incorporating any one of many possible amino acids. If 20 amino acids were being used in each randomization, the total number of different peptide sequences was 20 to the power of the number of residues so randomized. For a pentapeptide, 3.2 million different peptides are possible. Making a full representation of such a large collection is difficult to achieve synthetically, but peptides are generally not desirable for developing orally active pharmaceuticals. When combinatorial chemistry was adopted by the pharmaceutical sector, the chemical strategies changed toward making compounds either on ready-made scaffolds, or scaffold-free (eg, combining various amines with various carboxylic acids). During the first few years of the nonpeptide combinatorial era, the desire for large numbers of novel organic compounds drove a preference for making collections with more than two points of randomization. The resulting molecules tended to be too large and flexible to be good drug leads. These limitations of the second generation of combinatorial compounds made it difficult to convert biologically active hits seen generally in molecular assays into leads with desirable activities on cells or in vivo. The attrition rate at this step is highabout 90%. Therefore, designs are either avoiding scaffolds, or building heterocyclic scaffolds. Unlike a scaffold that simply orients randomized moieties in space, heterocycles often contribute directly to molecular recognition in addition to displaying randomized functionalities.
The synthetic methods used have also changed. The first generation libraries used solid phase peptide synthesis with parallel arrays, iterative synthesis, or split-mix methods to generate the permuted polymers ( Figure 1b) . Now, solution phase chemistry joins the combinatorial chemistry repertoire. Generally, this means that parallel synthesis is used for solution phase chemistries, and solid phase chemistry can use any combinatorial technique. Solid phase chemistry now includes tagged sorting approaches commercialized by IRORI.
There are several important observations about the second generation of combinatorial libraries that are generally known within the industry. As an illustration, data from a typical year of screening over half a million nonpeptide compounds from over 30 libraries tested for nearly 30 different projects of molecular and cellular assays will be summarized. It is no surprise that different library designs performed differently in a moderately wide range of screening campaigns. Sixteen of these
The Pharmacogenomics Journal libraries provided hit families with potencies less than 10 M. These libraries are plotted in Figure 2 showing the number of compounds tested per hit family vs the number of compounds made in the library. Less than half of the libraries with more than two randomizations yielded hits after screening with seven or more projects. Four out of six libraries with two randomizations yielded hits, and these are all shown in the extreme lower left corner of the plot. Surprisingly, these small collections of less than 8000 compounds combined accounted for 39% of the hit families discovered in spite of comprising less than 3% of the combinatorial compounds made. Moreover, half of the non-peptide leads generated came from combinatorial compounds with two randomized features. Thus, the binary design seems to provide an improvement of greater than 13-fold over what would be expected by chance alone. As an extreme case, the smallest library of 361 binary compounds with a lysyl scaffold generated one lead and two high quality, optimizable hit families (for a kinase and lipid enzyme) in a total of 14 screens. This is about a hundred-fold better at lead generation than is commonly seen industry-wide. These cases underscore the empowering nature of combinatorial chemistry at its best, given the right design and screening strategies. So the first lesson is keep the molecules small, simple and pharmacologically privileged.
The size of the library does not account for everything, however, and the scatter of six libraries of about 25 000 compounds each shows the range can extend from 120 000 compounds tested to 580 000 compounds tested for each hit family discovered (Figure 2 ). It is difficult to say whether this nearly 5-fold variation in efficiencies is accounted for by either design or luck in the mix of projects screened against the particular libraries.
Another theme is that the highdiversity second-generation libraries were effective in generating hits and leads for only certain types of screens. Table 1 lists the proportions of all hits distributed among the different screens. After correcting for the numbers of projects in the different classes, the ranking of the most effective to least effective screens progresses from protease targets, gene regulation, pro- tein kinases, and other enzymes followed by the rest of the screening classes. A central tenet of pharmacogenomics is that the expression patterns of different genes and target or clearance enzyme subtypes are important to therapeutic outcomes. Perhaps regulation of genes using future combinatorial chemistry will address this. Importantly, despite both antimicrobials and gene regulation being 'black box' cellular assays, the www.nature.com/tpj second-generation libraries did not perform so well with microbes. This is particularly striking since antibiotics are so often atypical from most orally active small molecules-generally including bulky compounds. Thus, certain target or screening classes performed better against the libraries of the recent past.
This lesson is clearly being applied as several organizations pursue the chemical biology of protein kinasesattempting to develop super-selective inhibitors of kinases that can inform us as to their biological roles and gain therapeutic advantage. 6 The ambitious goal of achieving super-selectivity will likely impact the course of pharmacogenomics where single nucleotide polymorphisms (SNPs) and single amino acid substitutions in drug targets may play an important role in disease or therapeutics. Thus, the unfolding story of combinatorial chemistry's foray into the chemical biology of protein kinases will probably lay fertile groundwork for applied pharmacogenomics.
A final theme emerging from the second-generation libraries is that regardless of the target class, the vast majority of hit families share a common rudimentary pharmacophore: a basic nitrogen and two lipophilic moieties (either aromatic or aliphatic). This empirical theme supports a recent proposal that charged functional groups contribute the most to affinity with the lowest cost to the molecular weight of the ligand, and combinatorial chemical libraries might take advantage of this.
7 Furthermore, most protein targets have a net negative charge, and the pharmacopoeia is replete with bioactive amines (eg, histamine antagonists).
In summary, the current third generation of combinatorial chemistry is building on its strengths. Design of the collections now employs hard-won empirical knowledge, sophisticated algorithms and medicinal chemistry. There is now a wealth of experience of what works and what doesn't, and there is tremendous potential in this technology as it comes of age. First generation computer programs for analysis of gene expression array data focused on pattern finding within the data values generated by one array, and the differential expression of genes using paired arrays. For these kinds of analyses, the most common format for organizing the data is a spreadsheet metaphor, usually with the genes of the array representing the rows and the columns representing experiments. Each intersection of row and column holds the expression value of a single position within the microarray (or in the case of GeneChips, a computed value such as the average difference between perfect match and mismatch probe sets 1 ). Viewed simply, the data are organized into a two-dimensional array that
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The Pharmacogenomics Journal 4 Houghten RA et al. Nature 1991; 354: 84-86. 5 Gold L. Harvey Lect 1995-96; 91: 47-57. 6 Gray NS et al. Science 1998; 281: 533-538. mimics the physical array from which it is derived. Widely used analysis utilities such as the Cluster and TreeView programs developed by Eisen et al 2 use a spreadsheet model for the individual values of one or multiple array experiments. Simplicity is both the strength and weakness of this approach to array data handling, because as the number of data sources to be compared grows, they eventually exceed the capacity of spreadsheet programs to store and efficiently manipulate the data. More importantly, there are inevitably additional characteristics of each location in the microarray that need to be included in the analysis (eg, GeneChip absent-present calls) and the best representation of the information is an n-dimensional array (n Ͼ 2), which is difficult to represent using a spreadsheet metaphor.
As the volume of array experiments grows, so does the need to turn to a generalizable database approach to storing the data. The simplest approach to database design emulates the spreadsheet, with one record-pergene and the fields of the database record storing the same information that would be present in the row-column intersections of a spreadsheet. In this data model, additional experiments generally lead to the necessity to modify the unit record structure of the database, creating additional fields for gene expression values. This approach also eventually meets structural limitations of a database management system, such as a maximum number of Linkage of gene expression data to other online sources of information supports the biological interpretation of expression patterns. Examples include links to reference utilities, such as the GenBank, LocusLink, and GeneCard databases, 6 and metabolic pathway information. 7 The biomedical literature describing the function of genes is potentially a useful source of information to explain expression patterns, and recently developed prototype systems link gene names as contained in the titles and abstracts of the literature, 8 and the MEDLINE Medical Subject Heading keywords applied to articles describing genes 9 as the basis for determining possible similarities among genes that share common expression characteristics. In these cases, the key element from the expression experiment that links to the external source is generally a unique identifier for each gene contained on the array. These identifiers often include GenBank accession numbers, Unigene identifiers, and Human Genome Organization (HUGO) gene names. Maintaining lists of equivalence and similarity between
